NCT00782301 - Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients | Biotech Hunter

Timeline

Start Date

March 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions

Hepatitis BHuman Immunodeficiency VirusHepatitis C, Chronic

Interventions

DRUG

maraviroc

maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.

DRUG

etravirine

etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.

Trial Locations (18)

10550

Pfizer Investigational Site, Mount Vernon

30308

Pfizer Investigational Site, Atlanta

30312

Pfizer Investigational Site, Atlanta

32803

Pfizer Investigational Site, Orlando

33305

Pfizer Investigational Site, Wilton Manors

33765

Pfizer Investigational Site, Clearwater

34695

Pfizer Investigational Site, Safety Harbor

70112

Pfizer Investigational Site, New Orleans

74135

Pfizer Investigational Site, Tulsa

75390

Pfizer Investigational Site, Dallas

77301

Pfizer Investigational Site, Conroe

77401

Pfizer Investigational Site, Bellaire

77477

Pfizer Investigational Site, Stafford

01605

Pfizer Investigational Site, Worcester

01655

Pfizer Investigational Site, Worcester

V6Z 2C7

Pfizer Investigational Site, Vancouver

M5G 2N2

Pfizer Investigational Site, Toronto

85-030

Pfizer Investigational Site, Bydgoszcz